Neutralizing Monoclonal Antibody Use and COVID-19 Infection Outcomes.

ABSTRACT:

Importance

Evidence on the effectiveness and safety of COVID-19 therapies across a diverse population with varied risk factors is needed to inform clinical practice.

Objective

To assess the safety of neutralizing monoclonal antibodies (nMAbs) for the treatment of COVID-19 and their association with adverse outcomes.

Design, setting, and participants

This retrospective cohort study included 167 183 patients from a consortium of 4 health care systems based in California, Minnesota, Texas, and Utah. The study included nonhospitalized patients 12 years and older with a positive COVID-19 laboratory test collected between November 9, 2020, and January 31, 2022, who met at least 1 emergency use authorization criterion for risk of a poor outcome.

Exposure

Four nMAb pro

SUBMITTER: Ambrose N 

PROVIDER: S-EPMC10126875 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature